| Pipeline

Our initial focus will be on dormant liver-stage malaria.

Cethromycin would be eligible for Fast Track and Breakthrough Therapy designation, Priority Review and Tropical Disease Priority Review Voucher (PRV). Additionally, Cethromycin would qualify for various development incentives of the Orphan Drug Act, including tax credits.